Jazz Pharmaceuticals (FRA:J7Z) EV-to-Revenue : 2.88 (As of Apr. 27, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Jazz Pharmaceuticals's enterprise value is €10,244 Mil. Jazz Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €3,556 Mil. Therefore, Jazz Pharmaceuticals's EV-to-Revenue for today is 2.88.

The historical rank and industry rank for Jazz Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:J7Z' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.87 Med: 5.56 Max: 12.18
Current: 2.86

During the past 13 years, the highest EV-to-Revenue of Jazz Pharmaceuticals was 12.18. The lowest was 2.87. And the median was 5.56.

FRA:J7Z's EV-to-Revenue is ranked better than
71.54% of 1033 companies
in the Biotechnology industry
Industry Median: 7.66 vs FRA:J7Z: 2.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-27), Jazz Pharmaceuticals's stock price is €101.40. Jazz Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €49.42. Therefore, Jazz Pharmaceuticals's PS Ratio for today is 2.05.

Jazz Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Jazz Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals EV-to-Revenue Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.20

3.97

4.33

4.10

3.08

Jazz Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															4.10	3.75	3.27	3.26	3.08

Competitive Comparison of Jazz Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Jazz Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jazz Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's EV-to-Revenue falls into.

Jazz Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Jazz Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	10244.248	/	3556.329
	=	2.88

Jazz Pharmaceuticals's current Enterprise Value is €10,244 Mil.
Jazz Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,556 Mil.

Jazz Pharmaceuticals (FRA:J7Z) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Jazz Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	101.40	/	49.416
	=	2.05

Jazz Pharmaceuticals's share price for today is €101.40.
Jazz Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €49.42.

Jazz Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines